PMA device
Supartz Joint Fluid Therapy
Seikagaku Corp. · Acid, Hyaluronic, Intraarticular (MOZ, Class III) · First FDA decision Jul 8, 2009, newest Jul 8, 2009Knee osteoarthritis
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
19
Naming "Supartz Joint Fluid"
MAUDE reports
0
Brand "Supartz Joint Fluid", since 2015
PubMed studies
0
Mentioning "Supartz Joint Fluid"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Supartz Joint Fluid Therapy
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 0 of 1 decisions filed under this name.
FDA's records could not be loaded.
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Supartz Joint Fluid", any status and sponsor, newest update first.
CGBio Inc.Not on our public-company list
NCT07468045 · 9 participants · Start Oct 9, 2024 · Primary completion Jul 7, 2025
Device: CG Synovia (Hyaluronic Acid 0.5%) · For: Arthroscopic Surgery
Sites: Jakarta, Indonesia · 2 sites in all
Chang Gung Memorial HospitalAcademic, hospital or other
NCT07819968 · 45 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 31, 2027
Device: Extracorporeal Shock Wave Therapy · For: Chronic Patellar Tendinopathy
Sites: Kaohsiung City, Taiwan
Chang Gung Memorial HospitalAcademic, hospital or other
NCT07819955 · 48 participants · Start Aug 4, 2023 · Primary completion Jun 27, 2025
Device: Extracorporeal Shock Wave Therapy · For: Osteoarthritis (OA)
Sites: Kaohsiung City, Taiwan
16 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Supartz Joint Fluid", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code MOZ
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Supartz Joint Fluid"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code MOZ.
- EUFLEXXA (1% Sodium Hyaluronate)Ferring Pharmaceuticals, Inc. · PMA 2017
- Gel-One(R)Seikagaku Corp. · PMA 2016
- Supartz FxSeikagaku Corp. · PMA 2016
- SupartzSeikagaku Corp. · PMA 2015
- Orthovisc High Molecular Weight HyaluronanAnika Therapeutics, Inc. · PMA 2011
- DurolaneBioventus, LLC · PMA 2020
- MonoviscAnika Therapeutics, Inc. · PMA 2020
- HyalganFidia Farmaceutici S.P.A. · PMA 2008
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.